APOE and Alzheimer disease: In the study, after changing the APOE4 allele to APOE3/3 genotype in iPSCs from two AD patients with CRISPR/Cas9, the edited neurons did not show significant differences in Aβ42 secretion levels compared with unedited APOE3 neurons, and these data suggest that the combination of CRISPR/Cas9 with stem cells has great potential for the diagnosis and treatment of AD (Lin et al., 2018) (Table 2).